Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simona Barbato

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Expert Review of Anticancer Therapy|May 27, 2024
Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myelomaPaola Tacchetti, Marco Talarico, Simona Barbato, et al.
Cancers|April 14, 2025
Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple MyelomaKatia Mancuso, Simona Barbato, Francesco Di Raimondo, et al.
Cancers|August 14, 2025
Correction: Mancuso et al. Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma. <i>Cancers</i> 2025, <i>17</i>, 1168Katia Mancuso, Simona Barbato, Francesco Di Raimondo, et al.
American Journal of Hematology|October 5, 2022
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myelomaPaola Tacchetti, Serena Rocchi, Elena Zamagni, et al.
Pharmaceuticals (Basel, Switzerland)|July 27, 2024
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients-A Systematic ReviewFlavia Bigi, Enrica Manzato, Simona Barbato, et al.
The New Microbiologica|October 21, 2015
First Italian Ebola virus disease case: management of hospital internal and external communicationLorella Salce, Simona Barbato, Daniela Renna, et al.
Clinical and Experimental Medicine|May 27, 2025
Ten-year experience on home care for patients with plasma cell disorders: bringing optimal therapy homeFlavia Bigi, Mauro Fiacchini, Roberta Restuccia, et al.
Leukemia & Lymphoma|March 18, 2021
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational studyIlaria Rizzello, Michele Cavo, Luca Dozza, et al.
Frontiers in Oncology|October 23, 2025
Case Report: Uncommon co-occurrence of different renal histopathological entities in a patient with multiple myeloma and lymphoplasmacytic lymphomaMarco Talarico, Gisella Vischini, Simona Barbato, et al.
Frontiers in Oncology|June 12, 2023
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myelomaKatia Mancuso, Elena Zamagni, Vincenza Solli, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Expert Review of Anticancer Therapy|May 27, 2024
Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myelomaPaola Tacchetti, Marco Talarico, Simona Barbato, et al.
Cancers|April 14, 2025
Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple MyelomaKatia Mancuso, Simona Barbato, Francesco Di Raimondo, et al.
Cancers|August 14, 2025
Correction: Mancuso et al. Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma. <i>Cancers</i> 2025, <i>17</i>, 1168Katia Mancuso, Simona Barbato, Francesco Di Raimondo, et al.
American Journal of Hematology|October 5, 2022
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myelomaPaola Tacchetti, Serena Rocchi, Elena Zamagni, et al.
Pharmaceuticals (Basel, Switzerland)|July 27, 2024
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients-A Systematic ReviewFlavia Bigi, Enrica Manzato, Simona Barbato, et al.
The New Microbiologica|October 21, 2015
First Italian Ebola virus disease case: management of hospital internal and external communicationLorella Salce, Simona Barbato, Daniela Renna, et al.
Clinical and Experimental Medicine|May 27, 2025
Ten-year experience on home care for patients with plasma cell disorders: bringing optimal therapy homeFlavia Bigi, Mauro Fiacchini, Roberta Restuccia, et al.
Leukemia & Lymphoma|March 18, 2021
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational studyIlaria Rizzello, Michele Cavo, Luca Dozza, et al.
Frontiers in Oncology|October 23, 2025
Case Report: Uncommon co-occurrence of different renal histopathological entities in a patient with multiple myeloma and lymphoplasmacytic lymphomaMarco Talarico, Gisella Vischini, Simona Barbato, et al.
Frontiers in Oncology|June 12, 2023
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myelomaKatia Mancuso, Elena Zamagni, Vincenza Solli, et al.
Pageof 3